钇-90 放射性栓塞治疗合并门静脉侵犯的肝细胞癌：米兰预后评分的验证。
Yttrium-90 Radioembolization for Hepatocellular Carcinoma with Portal Vein Invasion: Validation of the Milan Prognostic Score.
机构信息
Department of Interventional Radiology, Pisa University Hospital, via Paradisa 2, 56100 Pisa, Italy.
Department of Interventional Radiology, Pisa University Hospital, via Paradisa 2, 56100 Pisa, Italy.
出版信息
J Vasc Interv Radiol. 2020 Dec;31(12):2028-2032. doi: 10.1016/j.jvir.2020.06.027. Epub 2020 Oct 26.
The aim of the present study was to retrospectively analyze clinical outcomes of patients with hepatocellular carcinoma (HCC) and portal vein tumor thrombosis (PVTT) treated with yttrium-90 radioembolization stratified by Milan PVTT score according to PVTT extension, tumor burden, and bilirubin levels. Seventy patients were included and classified into good (n = 15; 21.4%), intermediate (n = 33; 47.1%), and dismal (n = 22; 31.4%) prognostic groups. Median overall survival durations were 24.6 mo, 13 mo (hazard ratio = 3.2; 95% confidence interval [CI], 1.2-9.7; P = .016), and 5.9 mo (hazard ratio = 4.1; 95% CI, 1.4-13.4; P = .0096), respectively. The Milan score represents an easy tool to select patients with HCC with PVTT who may benefit from radioembolization.
本研究旨在回顾性分析根据门静脉癌栓（PVTT）扩展、肿瘤负荷和胆红素水平分层的米兰 PVTT 评分，对接受钇-90 放射性栓塞治疗的肝细胞癌（HCC）和门静脉癌栓（PVTT）患者的临床结局。共纳入 70 例患者，分为预后良好（n=15；21.4%）、预后中等（n=33；47.1%）和预后不良（n=22；31.4%）三组。中位总生存期分别为 24.6 个月、13 个月（风险比=3.2；95%置信区间[CI]，1.2-9.7；P=.016）和 5.9 个月（风险比=4.1；95% CI，1.4-13.4；P=.0096）。米兰评分是一种简单的工具，可以选择可能从放射性栓塞治疗中获益的 HCC 合并 PVTT 患者。
Zotero 插件